Spinal Cord Stimulation in Boston

• When pain lasts for six months or longer, it is considered to be chronic pain. Chronic pain is most commonly experienced in the back or legs.
• Over 100 million Americans suffer from common chronic pain. Chronic pain is the primary cause of adult disability in the U.S.¹
• Severe pain can significantly interfere with a person’s quality of life and functionality, yet the condition is largely under-treated and misunderstood.
• There are many causes of chronic pain, including accidents, injuries, degenerative diseases, prior surgeries or even the aging process.
• Chronic pain is a costly public health issue. The combined loss of productivity and healthcare costs exceeds $600 billion annually in the U.S.¹

In 2014, U.S. retail pharmacies dispensed 245 million prescriptions for opioid pain relievers². Of these prescriptions, 65% were for short-term therapy³, but three to four percent of the adult population (9.6 million to 11.5 million persons) were prescribed longer-term opioid therapy.⁴

• Treatment options include over-the-counter medications, prescription medications, injections or invasive spinal surgery, however, for many patients, these options are inadequate for long term relief.
• Opioids, a commonly used tool in the management of chronic pain, also present addiction potential, long-term dependence and show little evidence of improved function.
• Opioids overdoses are the number one cause of preventable death in the United States.⁵ Opioid addiction rates have increased by 3000% from 2007 to 2014.⁶
• In July 2016, Congress passed legislation aimed at curbing opioid abuse and addiction.

• The category of spinal cord stimulation has been around for 35 years, however, HF10™ represents a major advance in patient outcomes.
• HF10™ is a small implantable medical device that sends mild electrical pulses to the spinal cord to alter pain signals traveling to the brain, thus reducing pain.
• HF10™ does not require drugs or major surgery, rather just a minimally invasive procedure.  
• HF10™ is a safe and established therapy that been used to treat over 31,000 patients globally.
• You can try HF10™ in a temporary trial to see if it is right for you.
• HF10™ is a major advance from traditional spinal cord stimulation devices because it works for more patients, and it provides better relief for both back and leg pain.
• The reason HF10™ is so effective is that it uses very mild imperceptible pulses at a high frequency to quiet the pain-causing nerves. This is very different from the older stimulators that work by creating tingling in the patient’s pain area to distract the patient from their pain. With HF10™ there is no tingling.
• HF10™ is FDA-approved for use while driving, which is another big advance vs. other stimulators.
• HF10™ is covered by Medicare and nearly all private insurers.

• The Senza® system delivering HF10™ was FDA approved in May 2015, which came with superiority labeling from the FDA over traditional SCS therapy, as well as the paresthesia-free indication.⁷ The approval was supported by clinically superior outcomes in the SENZA-RCT, the largest pivotal SCS randomized controlled trial (RCT) ever conducted.  
• HF10™ demonstrated superiority to traditional SCS therapy at all primary and secondary endpoints, resulting in better relief for back pain, better relief for leg pain and a more significant improvement in functionality. 12-month results were published in Anesthesiology and 24-month results were published in Neurosurgery, both of which demonstrated superiority to traditional SCS⁸.
• The SENZA-EU study showed remarkable reductions in both back pain scores and opioid intake. The number of patients not on opioids tripled from 14 to 42 percent at two years, and the average dose per patient was reduced by nearly 70 percent⁹ (84 mg to 27 mg).
• In the SENZA-NSRBP pilot study, results have demonstrated that patients with non-surgical refractory back pain who received HF10 experienced significant pain reduction at 36 months of follow-up. Additionally, 90% of patients were taking opioids at baseline, which reduced to only 12% of patients at 36 months¹⁰.